Drug candidates don’t usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up assets from one pharma on the cheap before being bought out for billions by another.
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions Read More »
Novo Nordisk goes “on the offensive” following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation makes it hard to predict what’s next.
As GLP-1s Hit Bargain Bin Prices, What’s the Future of the Obesity Market? Read More »
Sentir sed o hambre parece algo simple y cotidiano, pero detrás de estas sensaciones existe una compleja red de sensores biológicos, hormonas y circuitos cerebrales que trabajan para mantener el equilibrio interno del organismo. Comprender cómo se generan estas señales no …
The new features automatically share insurance details from more than 800,000 Medicare Advantage enrollees with providers to streamline check-in and verification.
Epic, Humana partner to speed patient check-in and coverage verification Read More »
The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta caused its own stock to drop during the gene therapy maker’s safety troubles this summer.
Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder Read More »
Pulsed field ablation sales grew by more than 300% in the second quarter for the company’s 2026 fiscal year, amid mounting competition in the space.
The health system blamed its performance for the quarter ended Sept. 30 on continued payer denials and cost challenges.
A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, if his CBER counterpart Vinay Prasad tries to supersede Pazdur’s authority, “there will be hell to pay.”
Makary Got His Man in Pazdur—But Can He Last as CDER Director? Read More »
Total spending in the safety-net insurance program is expected to grow 7.9% in fiscal year 2026, according to the survey. Meanwhile, states are facing significant federal cuts in the wake of the One Big Beautiful Bill Act.
States project flat Medicaid enrollment, increased spending as cuts loom: KFF Read More »
Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary hypertension, an indication that, according to BMO Capital Markets, has few treatment options.
Merck Extends Winrevair’s Win Streak With New Mid-Stage Data in Type of Hypertension Read More »
